Carlos Silva Rondon, MD
Medical Oncology · Pembroke Pines, FLNPI 1568776771
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 19 payments — averaging $49.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$176
- E.r. Squibb & Sons, L.L.C.$140
- Janssen Scientific Affairs, LLC$136
- Seagen Inc.$129
- Incyte Corporation$111
- Bristol Myers Squibb$74
- plus $167 from 6 others
Across 10 payments — averaging $12,343 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beone Medicines USA, Inc.$39K
- Beigene USA, Inc.$39K
- Beone Medicines Ltd.$34K
- Incyte Corporation$10K
- Janssen Research & Development, LLC$2K
What the payments were for
- Food & beverage$90997%
- Education$243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 2 | $176 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| Janssen Scientific Affairs, LLC | 2 | $136 |
| Seagen Inc. | 2 | $129 |
| Incyte Corporation | 1 | $111 |
| Bristol Myers Squibb | 1 | $74 |
| Gilead(2 entities) | 2 | $54 |
| Amgen | 2 | $30 |
| Novartis | 2 | $29 |
| Sanofi | 1 | $25 |
| Pfizer | 1 | $18 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$933 in reported general payments places this provider in the 15th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 15 | $261,814 |
| Acyclovir | 54 | $1,114 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $132 |
| Prednisone | 21 | $44 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Pembroke Pines
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.